ADPT
Adaptive Biotechnologies Corporation
Stock
$28.35+0.98 (+3.58%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $344M | $227M | $222M | $346M | $498M | $353M | $688M | $577M | $165M | — |
| Inventory | $10M | $9.8M | $8.4M | $14M | $14M | $19M | $14M | $9.1M | $7.8M | — |
| Current assets | $421M | $300M | $284M | $410M | $562M | $403M | $727M | $613M | $181M | — |
| Goodwill | $119M | $119M | $119M | $119M | $119M | $119M | $119M | $119M | $119M | — |
| Intangible assets | $884K | $1.7M | $3.4M | $5.1M | $6.8M | $8.5M | $10M | $12M | $14M | — |
| Total assets | $641M | $513M | $539M | $661M | $857M | $923M | $1.1B | $912M | $333M | — |
| Current liabilities | $88M | $90M | $98M | $88M | $110M | $114M | $105M | $78M | $23M | — |
| Long-term debt | $0 | $127M | $132M | $131M | $125M | — | — | — | — | — |
| Total liabilities | $490M | $288M | $337M | $353M | $393M | $319M | $373M | $341M | $30M | — |
| Shareholders' equity | $143M | $219M | $203M | $308M | $464M | $604M | $743M | $571M | −$258M | −$225M |
| Shares outstanding | 159.6M | 154.0M | 148.6M | 145.1M | 143.2M | 141.6M | 139.2M | 126.3M | — | — |
| Current ratio | 4.79 | 3.34 | 2.89 | 4.66 | 5.12 | 3.54 | 6.91 | 7.82 | 7.93 | — |